Ethanolic Extract Propolis-Loaded Niosomes Diminish Phospholipase B1, Biofilm Formation, and Intracellular Replication of Cryptococcus neoformans in Macrophages

Molecules. 2023 Aug 24;28(17):6224. doi: 10.3390/molecules28176224.

Abstract

Secretory phospholipase B1 (PLB1) and biofilms act as microbial virulence factors and play an important role in pulmonary cryptococcosis. This study aims to formulate the ethanolic extract of propolis-loaded niosomes (Nio-EEP) and evaluate the biological activities occurring during PLB1 production and biofilm formation of Cryptococcus neoformans. Some physicochemical characterizations of niosomes include a mean diameter of 270 nm in a spherical shape, a zeta-potential of -10.54 ± 1.37 mV, and 88.13 ± 0.01% entrapment efficiency. Nio-EEP can release EEP in a sustained manner and retains consistent physicochemical properties for a month. Nio-EEP has the capability to permeate the cellular membranes of C. neoformans, causing a significant decrease in the mRNA expression level of PLB1. Interestingly, biofilm formation, biofilm thickness, and the expression level of biofilm-related genes (UGD1 and UXS1) were also significantly reduced. Pre-treating with Nio-EEP prior to yeast infection reduced the intracellular replication of C. neoformans in alveolar macrophages by 47%. In conclusion, Nio-EEP mediates as an anti-virulence agent to inhibit PLB1 and biofilm production for preventing fungal colonization on lung epithelial cells and also decreases the intracellular replication of phagocytosed cryptococci. This nano-based EEP delivery might be a potential therapeutic strategy in the prophylaxis and treatment of pulmonary cryptococcosis in the future.

Keywords: Cryptococcus neoformans; biofilm formation; niosomes; phagocytosis; phospholipase B1; propolis; pulmonary cryptococcosis.

MeSH terms

  • Antifungal Agents* / chemistry
  • Antifungal Agents* / pharmacology
  • Biofilms* / drug effects
  • Cell Line, Tumor
  • Cryptococcosis / prevention & control
  • Cryptococcosis / therapy
  • Cryptococcus neoformans* / drug effects
  • Cryptococcus neoformans* / enzymology
  • Cryptococcus neoformans* / pathogenicity
  • Ethanol / chemistry
  • Fungal Proteins* / antagonists & inhibitors
  • Humans
  • Liposomes
  • Lung Diseases, Fungal / prevention & control
  • Lung Diseases, Fungal / therapy
  • Lysophospholipase* / antagonists & inhibitors
  • Macrophages, Alveolar* / microbiology
  • Propolis* / chemistry
  • Propolis* / pharmacology
  • Virulence / drug effects
  • Virulence Factors / antagonists & inhibitors

Substances

  • Ethanol
  • Fungal Proteins
  • Liposomes
  • Lysophospholipase
  • Propolis
  • Virulence Factors
  • Antifungal Agents